Related Experiment Video

Updated: May 13, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Current approaches for the treatment of multiple myeloma

Reiko Watanabe1, Michihide Tokuhira, Masahiro Kizaki

  • 1Division of Hematology, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe, Saitama, 350-8550, Japan. reikow@saitama-med.ac.jp

International Journal of Hematology
|March 12, 2013
PubMed

Insights

Novel therapies like bortezomib have improved multiple myeloma outcomes. This review examines optimal first-line regimens, transplantation criteria, and post-therapy strategies for better patient management.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Recent advances in multiple myeloma therapeutics include proteasome inhibitors (e.g., bortezomib) and immunomodulatory drugs (e.g., lenalidomide, thalidomide).
  • These agents have significantly improved patient outcomes in multiple myeloma treatment.
  • Despite progress, key therapeutic questions remain unresolved.

Purpose of the Study:

  • To review clinical evidence regarding optimal first-line therapy for multiple myeloma.
  • To explore current controversies in patient selection for autologous or allogeneic transplantation.
  • To examine the role of consolidation and maintenance therapy in responding patients.

Main Methods:

  • Review of clinical evidence from previous studies.
  • Analysis of ongoing clinical trials and their implications.
  • Synthesis of data to address therapeutic controversies.

Main Results:

  • Evidence suggests evolving standards for first-line treatment selection.
  • Guidelines for autologous and allogeneic transplantation are being refined.
  • The optimal use of consolidation and maintenance therapy requires further clarification.

Conclusions:

  • Further research and consensus are needed to standardize multiple myeloma treatment protocols.
  • Personalized therapeutic strategies are essential for maximizing patient benefit.
  • Addressing current controversies will enhance the management of multiple myeloma.

More Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...